GlassScriptPhysician profile
Sara Seider
NPI 1598449910
$1,619.64
in general payments reported to CMS, 2019-2025
25 companies · $594 in 2025
The $594 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $420 · 2024: $605 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,521 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,520.64 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $202.20 | 2023-2024 | Ingrezza |
| Janssen Biotech, INC. | $159.48 | 2025 | Tremfya |
| Amgen INC. | $155.55 | 2025 | Evenity, Tavneos, Otezla |
| Ucb, INC. | $140.38 | 2024-2025 | Bimzelx, Nayzilam, Briviact |
| Novartis Pharmaceuticals Corporation | $137.89 | 2023-2025 | |
| Lilly USA, LLC | $107.55 | 2023 | Trulicity |
| Otsuka America Pharmaceutical, INC. | $86.70 | 2023-2024 | Rexulti, Nuedexta |
| Sumitomo Pharma America, INC. | $64.02 | 2024 | Aptiom |
| Astellas Pharma US INC | $63.16 | 2023-2024 | Veozah |
| Mallinckrodt Hospital Products INC. | $60.52 | 2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $51.12 | 2024 | Farxiga |
| Neurelis, INC. | $50.44 | 2023-2024 | Valtoco |
| Amphastar Pharmaceuticals, INC. | $49.44 | 2023-2024 | Baqsimi |
| Teva Pharmaceuticals USA, INC. | $47.53 | 2024 | Austedo Xr, Uzedy |
| Bayer Healthcare Pharmaceuticals INC. | $34.54 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $30.97 | 2025 | Actemra, Gazyva |
| Boston Scientific Corporation | $26.55 | 2023 | Watchman Flx |
| Ani Pharmaceuticals, INC. | $24.21 | 2025 | Purified Cortrophin Gel |
| Averitas Pharma INC. | $23.47 | 2024 | Qutenza |
| Abbvie INC. | $22.69 | 2025 | |
| Lundbeck LLC | $20.87 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $20.21 | 2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.29 | 2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $16.76 | 2024 | Keveyis |
| Janssen Pharmaceuticals, INC | $4.10 | 2023 | Invega Sustenna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Seider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.